Cytori Therapeutics Inc (CYTX) Rating Reiterated by B. Riley

Cytori Therapeutics Inc (NASDAQ:CYTX)‘s stock had its “hold” rating reissued by analysts at B. Riley in a note issued to investors on Tuesday. B. Riley also issued estimates for Cytori Therapeutics’ Q3 2017 earnings at ($0.16) EPS, Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($0.67) EPS, Q2 2018 earnings at ($0.04) EPS, Q3 2018 earnings at ($0.04) EPS and Q4 2018 earnings at ($0.04) EPS.

A number of other equities research analysts have also recently commented on CYTX. Maxim Group set a $5.00 target price on shares of Cytori Therapeutics and gave the company a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research cut shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, ValuEngine cut shares of Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

Shares of Cytori Therapeutics (NASDAQ CYTX) traded down $0.03 on Tuesday, hitting $0.37. 388,400 shares of the stock traded hands, compared to its average volume of 772,567. Cytori Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The firm had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $2.04 million. During the same quarter in the prior year, the company earned ($0.26) EPS. research analysts expect that Cytori Therapeutics will post -0.67 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Cytori Therapeutics Inc (CYTX) Rating Reiterated by B. Riley” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/07/cytori-therapeutics-inc-cytx-rating-reiterated-by-b-riley.html.

A number of large investors have recently bought and sold shares of CYTX. Perkins Capital Management Inc. lifted its position in Cytori Therapeutics by 99.0% during the second quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock valued at $962,000 after acquiring an additional 435,217 shares during the last quarter. Sabby Management LLC increased its stake in Cytori Therapeutics by 28.0% during the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after purchasing an additional 355,504 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Cytori Therapeutics by 81.9% during the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after purchasing an additional 275,653 shares in the last quarter. 12.02% of the stock is owned by institutional investors.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply